Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: Evidence in patients with acute myocardial infarction

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 4, 2013, Pages 512-518

  Paradela Dobarro, Beatriz ^a   Raposeiras Roubín, Sergio ^a,b   Rodiño Janeiro, Bruno K ^a,e   Grigorian Shamagian, Lilian ^c   García Acuña, José M ^b   Aguiar Souto, Pablo ^b   Jacquet Hervet, Michel ^b   Reino Maceiras, María V ^b   González Juanatey, José R ^a,b,d   Álvarez, Ezequiel ^a,b,d  

^a Santiago University Clinical Hospital   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e EUROPEAN MOLECULAR BIOLOGY LABORATORY   (France)

Author keywords

Acute myocardial infarction; Advanced glycation end products (AGEs); Cardiovascular biomarkers; High sensitivity C reactive protein (hsCRP); Statins

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; DRUG MECHANISM; DYSLIPIDEMIA; FEEDBACK SYSTEM; FEMALE; GLYCATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 84879481084     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.05.001     Document Type: Article

References (30)

1. Arnaud, C., Burger, F., Steffens, S., Veillard, N.R., Nguyen, T.H., Trono, D., Mach, F.o., 2005. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes. Arteriosclerosis, Thrombosis, and Vascular Biology 25, 1231-1236.
2. Balasubramaniam, K., Viswanathan, G.N., Marshall, S.M., Zaman, A.G., 2012. Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. Cardiology Research and Practice.
3. Basta, G., Lazzerini, G., Massaro, M., Simoncini, T., Tanganelli, P., Fu, C., Kislinger, T., Stern, D.M., Schmidt, A.M., De Caterina, R., 2002. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE. Circulation 105, 816-822.
4. Bierhaus, A., Humpert, P., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D., Nawroth, P., 2005. Understanding RAGE, the receptor for advanced glycation end products. Journal of Molecular Medicine 83, 876-886. (Pubitemid 41598688)
5. Brownlee, M., 2000. Negative consequences of glycation. Metabolism 49, 9-13. (Pubitemid 30091786)
6. Byington, R.P., Jukema, J.W., Salonen, J.T., Pitt, B., Bruschke, A.V., Hoen, H., Furberg, C.D., Mancini, G.B.J., 1995. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 92, 2419-2425.
7. Calkin, A., Giunti, S., Sheehy, K., Chew, C., Boolell, V., Rajaram, Y., Cooper, M., Jandeleit-Dahm, K., 2008. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 51, 1731-1740.
8. Chen, J., Jin, J., Song, M., Dong, H., Zhao, G., Huang, L., 2012. C-reactive protein downregulates endothelial nitric oxide synthase expression and promotes apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts. Gene 496, 128-135.
9. Davignon, J., 2004. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III-39-III-43.
10. Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A., Langendorfer, A., Stein, E.A., Kruyer, W., Gotto, A.M.J., 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279, 1615-1622. (Pubitemid 28248586)
11. Feng, B., Xu, L., Wang, H., Yan, X., Xue, J., Liu, F., Hu, J.-F., 2011. Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1812, 1130-1137.
12. Fornengo, P., Bosio, A., Epifani, G., Pallisco, O., Mancuso, A., Pascale, C., 2006. Prevalence of silent myocardial ischaemia in new-onset middle-aged Type 2 diabetic patients without other cardiovascular risk factors. Diabetic Medicine 23, 775-779. (Pubitemid 44366077)
13. Gabay, C., Kushner, I., 1999. Acute-phase proteins and other systemic responses to inflammation. New England Journal of Medicine 340, 448-454. (Pubitemid 29084777)
14. Hölschermann, H., Schuster, D., Parviz, B., Haberbosch, W., Tillmanns, H., Muth, H., 2006. Statins prevent NF-kB transactivation independently of the IKK-pathway in human endothelial cells. Atherosclerosis 185, 240-245.
15. Huang, X., Zhang, J., Liu, J., Sun, L., Zhao, H., Lu, Y., Wang, J., Li, J., 2012. C-reactive protein promotes adhesion of monocytes to endothelial cells via NADPH oxidase-mediated oxidative stress. Journal of Cellular Biochemistry 113, 857-867.
16. Jakus, V., 2000. The role of free radicals, oxidative stress and antioxidant systems in diabetic vascular disease. Bratislavske lekarske listy 101, 541-551.
17. Jakus, V., Rietbrock, N., 2004. Advanced glycation end-products and the progress of diabetic vascular complications. Physiological Research 53, 131-142. (Pubitemid 38525116)
18. Jialal, I., Stein, D., Balis, D., Grundy, S.M., Adams-Huet, B., Devaraj, S., 2001. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103, 1933-1935. (Pubitemid 32322218)
19. Levine, G.N., Keaney, J.F., Vita, J.A., 1995. Cholesterol reduction in cardiovascular disease-clinical benefits and possible mechanisms. New England Journal of Medicine 332, 512-521.
20. Mahajan, N., Bahl, A., Dhawan, V., 2010. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGEs) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. International Journal of Cardiology 142, 273-278.
21. Münch, G., Keis, R., Wessels, A., Riederer, P., Bahner, U., Heidland, A., Niwa, T., Lemke, H.-D., Schinzel, R., 1997. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Clinical Chemistry and Laboratory Medicine 25, 669.
22. Raposeiras-Roubín, S., Rodiño-Janeiro, B.K., Grigorian-Shamagian, L., Moure-González, M., Seoane-Blanco, A., Varela-Román, A., Álvarez, E., González-Juanatey, J.R., 2010. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels. European Journal of Heart Failure 12, 1092-1100.
23. Schmidt, A.-M., Hofmann, M., Taguchi, A., Yan, S.D., Stern, D.M., 2000. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Seminars Thrombosis Hemostasis 26 (485), 494.
24. Scirica, B.M., Morrow, D.A., 2006. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 113, 2128-2151.
25. Tan, K.C.B., Chow, W.-S., Tam, S., Bucala, R., Betteridge, J., 2004. Association between acute-phase reactants and advanced glycation end products in Type 2 diabetes. Diabetes Care 27, 223-228. (Pubitemid 38196736)
26. Thygesen, K., Alpert, J.S., White, H.D., Jaffe, A.S., Apple, F.S., Galvani, M., Katus, H.A., Newby, L.K., Ravkilde, J., Chaitman, B., Clemmensen, P.M., Dellborg, M., Hod, H., Porela, P., Underwood, R., Bax, J.J., Beller, G.A., Bonow, R., Van der Wall, E.E., Bassand, J.P., Wijns, W., Ferguson, T.B., Steg, P.G., Uretsky, B.F., Williams, D.O., Armstrong, P.W., Antman, E.M., Fox, K.A., Hamm, C.W., Ohman, E.M., Simoons, M.L., Poole-Wilson, P.A., Gurfinkel, E.P., Lopez-Sendon, J.L., Pais, P., Mendis, S., Zhu, J.R., Wallentin, L.C., Fernandez-Aviles, F., Fox, K.M., Parkhomenko, A.N., Priori, S.G., Tendera, M., Voipio-Pulkki, L.M., Vahanian, A., Camm, A.J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S.D., McGregor, K., Sechtem, U., Silber, S., Widimsky, P., Zamorano, J.L., Morais, J., Brener, S., Harrington, R., Morrow, D., Lim, M., Martinez-Rios, M.A., Steinhubl, S., Levine, G.N., Gibler, W.B., Goff, D., Tubaro, M., Dudek, D., Al-Attar, N., 2006. Universal definition of myocardial infarction. Circulation 116, 2634-2653. (Pubitemid 350182388)
27. Venugopal, S.K., Devaraj, S., Yuhanna, I., Shaul, P., Jialal, I., 2002. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106, 1439-1441.
28. Yeh, E.T.H., Willerson, J.T., 2003. Coming of age of C-reactive protein. Circulation 107, 370-371.
29. Yoshida, T., Yamagishi, S.-i., Nakamura, K., Matsui, T., Imaizumi, T., Takeuchi, M., Ueno, T., Sata, M., 2006. Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Letters 580, 2788-2796.
30. Zhong, Y., Li, S.-H., Liu, S.-M., Szmitko, P.E., He, X.-Q., Fedak, P.W.M., Verma, S., 2006. C-reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 48, 504-511. (Pubitemid 44253747)